Bosutinib: a SRC–ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia
Fuad El Rassi, Hanna Jean KhouryDivision of Hematology, Department of Hematology and Medical Oncology, the Winship Cancer Institute at Emory University, Atlanta, Georgia, USAAbstract: Bosutinib is one of five tyrosine kinase inhibitors commercially available in the United States for the treatment of...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2013-08-01
|
| Series: | Pharmacogenomics and Personalized Medicine |
| Online Access: | http://www.dovepress.com/bosutinib-a-srcndashabl-tyrosine-kinase-inhibitor-for-treatment-of-chr-a13902 |